O

Orion Oyj
OMXH:ORNBV

Watchlist Manager
Orion Oyj
OMXH:ORNBV
Watchlist
Price: 42.44 EUR -0.79% Market Closed
Market Cap: 6B EUR
Have any thoughts about
Orion Oyj?
Write Note

Orion Oyj
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Orion Oyj
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
O
Orion Oyj
OMXH:ORNBV
Intangible Assets
€116.9m
CAGR 3-Years
55%
CAGR 5-Years
21%
CAGR 10-Years
8%
H
Herantis Pharma Oyj
OMXH:HRTIS
Intangible Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Orion Oyj
Glance View

Market Cap
6B EUR
Industry
Pharmaceuticals

Orion Oyj, a stalwart in the pharmaceutical industry, has carved out a significant niche for itself since its inception in Finland. The company was founded in 1917, and over the years, it has evolved into a crucial player in the global medical landscape. As a fully integrated pharmaceutical entity, Orion’s operations encompass everything from research and development to manufacturing and distribution. Its primary areas of focus include the development of therapies for central nervous system disorders, oncology, and respiratory diseases, as well as a selection of veterinary medicines and active pharmaceutical ingredients (APIs). This comprehensive approach enables Orion to maintain control over the entire drug production pipeline, ensuring quality and innovation are at the forefront of its mission. Orion's business strategy revolves around a robust combination of proprietary innovations and strategic partnerships. The company invests heavily in R&D, dedicating a substantial portion of its revenue to discovering and developing new drugs. By doing so, it fortifies its product pipeline, ensuring a steady influx of new offerings that cater to unmet medical needs, fostering a competitive edge in the market. Additionally, Orion supplements its earnings through collaborations with other pharmaceutical giants, expanding its market reach and sharing resources to mitigate risks associated with the costly drug development process. Through this dual approach of in-house excellence and collaborative ventures, Orion Oyj effectively sustains its financial health, continually fueling its growth and ensuring it remains a formidable force in the international pharmaceutical arena.

ORNBV Intrinsic Value
53.98 EUR
Undervaluation 21%
Intrinsic Value
Price
O

See Also

What is Orion Oyj's Intangible Assets?
Intangible Assets
116.9m EUR

Based on the financial report for Jun 30, 2024, Orion Oyj's Intangible Assets amounts to 116.9m EUR.

What is Orion Oyj's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
8%

Over the last year, the Intangible Assets growth was 13%. The average annual Intangible Assets growth rates for Orion Oyj have been 55% over the past three years , 21% over the past five years , and 8% over the past ten years .

Back to Top